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Plan of the lecture   
• Leukaemia’ General 
Overview 
• Major kinds of leukemia 
(acute myelogenous & 
lymphoblastic, chronic 
myelogenous & lymphocytic) 
• Abbreviations  
• Diagnostic guidelines 
 https://www.thinglink.com/scene/632991493535039488  
LEUKAEMIA’ GENERAL OVERVIEW 
Definition  
Leukemia (leukaemia) is a group of progressive, 
malignant neoplasms (cancers) of the blood-forming 
organs, marked by diffuse replacement of the bone 
marrow development of leukocytes and their 
precursors in the blood and bone marrow, 
accompanied by a reduced number of erythrocytes 
and blood platelets, and resulting in anemia, 
increased susceptibility to infection and hemorrhage 
with weakness and malaise, fever, pain in the joints 
and bones, swelling of the lymph nodes, spleen, and 
liver.  
Epidemiology 1 
http://media-2.web.britannica.com/eb-media/15/67715-004-DD03B367.jpg  
Epidemiology 2 
http://media-2.web.britannica.com/eb-media/15/67715-004-DD03B367.jpg  
Risk Factors 
Acute leukemia 
• Chronic exposure to certain chemicals (for example 
benzene)   
• Long-term treatment with alkylating substances 
and ionizing radiation  
• Mutations in cellular oncogenes, tumor suppressor 
genes, and transcription factors   
 
http://oncolex.org/leukemia/background/etiology  
Risk Factors 
Chronic leukemia 
• Sex (men: women is 2:1) and genetic factors  (1st 
degree relatives of patients have a more than 3 
times greater chance to develop leukemia) 
• East Asian region   
• Certain retroviruses (some rare cases of T-cell 
leukemia are associated with infection of a human 
retrovirus (HTLV I) 
http://oncolex.org/leukemia/background/etiology  
Etiology     
• In almost all cases, the etiology is unknown 
• Different kinds of leukemia are believed to have 
different causes 
• Abnormalities of chromosomes have been found in 
various types of leukemia 
• Whether chromosomal alterations are primary or 
secondary is undetermined, but they are at least 
contributory in the development of leukemia 
• There is an increasing body of evidence incriminating 
viruses in leukemogenesis in man, and they may be a 
factor in all cases 
• Certain chemicals and ionizing radiation  may be 
important etiologic factors in a few cases 
https://en.wikipedia.org/wiki/Leukemia, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1516260/   
Classification 1 
four major kinds of leukemia   
https://en.wikipedia.org/wiki/Leukemia  
Cell type Acute Chronic 
Myelogenous 
leukemia 
("myeloid" or 
"nonlymphocytic") 
Acute 
myelogenous 
leukemia (AML 
or myeloblastic) 
Chronic 
myelogenous 
leukemia 
(CML) 
Lymphocytic 
leukemia 
(or "lymphoblastic") 
Acute 
lymphoblastic 
leukemia (ALL) 
Chronic 
lymphocytic 
leukemia 
(CLL) 
Classification 2 
Myeloid Leukemia   
http://medrevise.co.uk/images/thumb/e/e1/All.jpg/450px-All.jpg  
Classification 3 
Lymphoid Leukemia  
http://medrevise.co.uk/images/thumb/e/e1/All.jpg/450px-All.jpg  
MAJOR KINDS OF LEUKEMIA 
(ACUTE MYELOGENOUS & LYMPHOBLASTIC, CHRONIC 
MYELOGENOUS & LYMPHOCYTIC) 
Acute myelogenous leukemia (AML): 
definition 
Acute myelogenous (myeloid, nonlymphocytic) 
leukemia (AML) represents a group of clonal 
hematopoietic stem cell disorders in which both a 
block in differentiation and unchecked proliferation 
result in the accumulation of myeloblasts at the 
expense of normal hematopoietic precursors  
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/acute-myelogenous-leukemia/ 
Acute myelogenous leukemia (AML): 
epidemiology 
AML is the most common acute leukemia affecting 
adults, and its incidence increases with age 
http://www.bloodjournal.org/content/bloodjournal/113/18/4179/F1.large.jpg?sso-checked=true  
Acute myelogenous leukemia (AML): 
The French-American-British (FAB) classification 
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-classified  
FAB subtype Name 
M0 Undifferentiated acute myeloblastic leukemia 
M1 Acute myeloblastic leukemia with minimal maturation 
M2 Acute myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia (APL) 
M4 Acute myelomonocytic leukemia 
M4 eos Acute myelomonocytic leukemia with eosinophilia 
M5 Acute monocytic leukemia 
M6 Acute erythroid leukemia 
M7 Acute megakaryoblastic leukemia 
 
 
Acute myelogenous leukemia (AML): 
WHO classification 
• AML with certain genetic abnormalities (translocation 
between chromosomes 8 and 21, translocation or inversion 
in chromosome 16,  translocation between chromosomes 9 
and 11, etc.)  
• AML with myelodysplasia-related changes 
• AML related to previous chemotherapy or radiation 
• AML not otherwise specified (with minimal differentiation 
(M0), without maturation (M1), with maturation (M2), etc.)  
• Myeloid sarcoma (granulocytic sarcoma or chloroma) 
• Myeloid proliferations related to Down syndrome 
• Undifferentiated and biphenotypic acute leukemias   
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-classified  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 1 
Initial clinical presentations are related to 
pancytopenia, the reduction of all cell counts, 
reflecting the leukemic cell replacement of 
bone marrow and include: 
• Headache/disorientation due to abnormal white 
blood cells infiltrating the central nervous system 
(CNS)  
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Characteristics.2FClinical_Presentation  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 2 
• Anemia which is accompanied by pallor, fatigue, 
malaise, hypoxia, and bleeding, caused by rapidly 
proliferating leukocytes inhibiting formation of 
erythrocytes and thrombocytes 
• Infections (pneumonia) and mouth/throat 
ulcerations, caused by increased numbers of 
immature or abnormal leukocytes which are unable 
to fight off infections  
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Characteristics.2FClinical_Presentation  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 3 
• Increased metabolic rate with weakness, pallor, and 
weight loss, caused by increased leukocyte 
production which require increased nutrient 
production; destruction of cells also increases 
metabolic waste  
• Hyperuricemia which may lead to renal pain, 
obstruction, and infection (later development 
includes renal insufficiency with uremia), caused by 
a great number of leukocytes being destroyed 
which releases large amounts of uric acid; in late 
stages, leukocytes infiltrate the kidneys 
 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Characteristics.2FClinical_Presentation  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 4 
• Enlarged organs (spleen, liver), caused by increased 
number of white blood cells accumulating within 
liver and spleen causing tissue distension 
• Lymphadenopathy and bone pain, caused by 
excessive number of white blood cells accumulating 
in lymph nodes and bone marrow 
• Bone discomfort (especially in ribs, sternum, and 
tibia) 
• Older adults may experience delirium, and 
progressive weakness 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Characteristics.2FClinical_Presentation  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 5 
Paleness of 
skin 
http://discussingaml.blogspot.com/2015_04_01_archive.html  
 
 
Unexplained 
bruising 
Petechiae 
Acute myelogenous leukemia (AML): 
clinical presentation 6 
Severe generalized gingival overgrowth with localized 
necrosis and sloughing involving the interdental 
papilla http://discussingaml.blogspot.com/2015_04_01_archive.html  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 7 
Signs and symptoms of acute myeloid leukemia 
http://leukemiasymptomsander.blogspot.com/2015/10/signs-and-symptoms-of-acute-myeloid.html  
 
 
Acute myelogenous leukemia (AML): 
diagnosis 1 
• History and Physical Examination: clinical presentation 
• Blood Test: leukocytosis, sometimes leukemic blasts, 
isolated decreases in platelets, red blood cells, or even with 
a low white blood cell count (leukopenia) 
• Bone marrow biopsy and aspiration: to diagnose the 
presence of leukemia, to differentiate AML from other 
types of leukemia (e.g. acute lymphoblastic leukemia - ALL), 
and to identify the subtype of AML accordingly to its 
classifications   
• Immunophenotyping: to determine the subtype of AML by 
comparing the cancer cells to normal cells in the immune 
system  
https://en.wikipedia.org/wiki/Acute_myeloid_leukemia  
 
 
Acute myelogenous leukemia (AML): 
diagnosis 2 
The following conditions  require differentiation: 
• Acute Lymphoblastic Leukemia (ALL) 
• Agnogenic Myeloid Metaplasia with Myelofibrosis 
• Anemia 
• Bone Marrow Failure 
• Chronic Myelogenous Leukemia 
• Lymphoma, B-cell, Lymphoblastic 
• Myelodysplastic Syndrome 
• Agranulocytosis (severe subset of neutropenia) 
• Myelophthisic Anemia 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute myelogenous leukemia (AML): 
diagnosis 3 
Malignant myeloid cells  
http://imagebank.hematology.org/AssetDetail.aspx?AssetID=3356 https://www.oumedicine.com/pathology/education/web-based-learning/case-reports/case-1  
http://pathology.jhu.edu/cytopath_tut/Considerations/ShowImage.cfm?ModuleID=3&CaseInfoID=27&ImageID=531&ConsiderID=156  
 
 
Acute myelogenous leukemia (AML): 
diagnosis  
Immunophenotyping 
http://wiki.clinicalflow.com/Cases/Case_List/Acute_Myelogenous_Leukemia_(AML)_not_otherwise_categorized_-_General_Information/AMML_(Acute_Myelomonocytic_Leukemia)_(M4)  
 
 
Acute myelogenous leukemia (AML): 
treatment 1 
There are 4 types of standard treatments: 
1) Chemotherapy: systemic,  intrathecal (the spinal canal, the 
subarachnoid space), or regional drugs  usage depends of 
the AML subtype   
2) Radiation: different types of radiation to kill cancer cells or 
keep them from growing through  external and internal  
approaches which depend of the AML subtype 
3) Stem Cell Transplant: method of administering chemo and 
replacing blood forming cells   
4) Targeted Therapy: monoclonal antibodies or other 
substances to destroy specific cancer cells without 
harming the patient's normal cells 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute myelogenous leukemia (AML): 
treatment 2 
The primary treatment is chemotherapy (three phases): 
• The first  (Induction) phase clears the blood of leukemia 
cells and reduces the number of blasts in the bone marrow 
with the goal to return blood counts to a normal level over 
time and to reach a complete remission 
• The second (Consolidation) phase is administered after a 
rest period where the patient recovers from the first phase 
with the goal to kill the leukemia cells that are still present  
• The third (Maintenance) phase is necessary in only certain 
types of leukemia and includes giving low doses of a chemo 
drug for months or years after the consolidation phase  
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute myelogenous leukemia (AML): 
prognosis 
• Acute myeloid leukemia is a curable disease, and the 
chance of cure for a specific patient depends on a number 
of prognostic factors 
• Increasing age is an adverse factor, because older patients 
more frequently have a previous antecedent hematologic 
disorder along with comorbid medical conditions that 
compromise the ability to give full doses of chemotherapy 
• A previous antecedent hematologic disorder is associated 
with a poor outcome to therapy 
http://emedicine.medscape.com/article/197802-overview#a6  
 
 
Acute lymphoblastic leukemia (ALL): 
definition 
Acute lymphoblastic (lymphocytic, lymphoid) 
leukemia (ALL) represents a group of clonal 
hematopoietic stem cell disorders in which both a 
block in differentiation and unchecked proliferation 
result in the accumulation of  lymphoblasts at the 
expense of normal hematopoietic precursors  
https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia  
Acute lymphoblastic  leukemia (ALL): 
epidemiology 
Incidence of acute lymphoblastic leukemia (ALL)       
by age 
http://asheducationbook.hematologylibrary.org/content/2006/1/128/F1.expansion  
Acute lymphoblastic  leukemia (ALL): 
The French-American-British (FAB) classification 
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-classified  
 
 
Division of ALL according to FAB criteria 
L1 – cytoplasma-deficient, small blasts 
L2 – more heterogenous with emphasis on cytoplasma 
richness and size 
L3 – B-cell blasts with basophile 
vacuolized cytoplasma  
Acute lymphoblastic  leukemia (ALL): 
WHO classification 
http://imaging.ubmmedica.com/cancernetwork/cmhb13/13_29_Table2.gif  
 
 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 1 
• Anemia 
• Dizziness 
• Weakness 
• Fatigue 
• Shortness of breath 
• Frequent or unexplained fever and infection 
• Weight loss and/or loss of appetite 
• Bleeding from the gums and/or nose 
• Pale skin  
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 2 
• Excessive and unexplained bruising due to 
low platelet levels 
• Swollen lymph nodes (neck, underarm, groin, 
stomach) 
• Bone pain, joint pain (the spread of "blast" cells 
from the marrow cavity) 
• Pitting edema (swelling) in the lower limbs and/or 
abdomen  
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 3 
Paleness of 
skin 
http://www.texaschildrensblog.org/2013/01/my-2-year-old-son-survived-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/  
http://leukemiasymptomsander.blogspot.com/2015/02/leukemia-symptoms-petechiae.html  
 
 
Unexplained 
bruising 
Petechiae 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 4 
Severe generalized gingival overgrowth with localized 
necrosis and sloughing involving the interdental 
papilla http://discussingaml.blogspot.com/2015_04_01_archive.html  
 
 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 5 
Signs and symptoms of acute lymphoblastic leukemia 
http://leukemiasymptomsander.blogspot.com/2015/10/signs-and-symptoms-of-acute-myeloid.html  
 
 
Acute lymphoblastic  leukemia (ALL): 
diagnosis 1 
• History and Physical Examination: clinical presentation 
• Blood Test: leukocytosis, sometimes leukemic blasts, 
isolated decreases in platelets, red blood cells, or even with 
a low white blood cell count (leukopenia) 
• Bone marrow biopsy and aspiration: the presence of 
leukemia, differentiation ALL from other types of leukemia, 
identifying the subtype of ALL 
• Immunophenotyping: to determine the subtype of ALL by 
comparing the cancer cells to normal cells in the immune 
system   
https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia#Pathophysiology  
 
 
Acute lymphoblastic  leukemia (ALL): 
diagnosis 2 
The following conditions  require differentiation: 
• Acute Lymphoblastic Leukemia (ALL) 
• Agnogenic Myeloid Metaplasia with Myelofibrosis 
• Anemia 
• Bone Marrow Failure 
• Chronic Myelogenous Leukemia 
• Lymphoma, B-cell, Lymphoblastic 
• Myelodysplastic Syndrome 
• Agranulocytosis (severe subset of neutropenia) 
• Myelophthisic Anemia 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute lymphoblastic  leukemia (ALL): 
diagnosis 3 
Malignant lymphoblastic cells  
https://en.wikipedia.org/wiki/B-cell_lymphoma https://www.pinterest.com/pin/287526757435867609/ http://www.donationto.com/blog/fundraising-for-acute-lymphoblastic-leukemia-all/ 
  
 
 
Acute lymphoblastic  leukemia (ALL): 
diagnosis  
Immunophenotyping 
http://bitesizebio.com/22238/immunophenotyping-identifying-whos-who-in-the-cellular-world/  
 
 
Acute lymphoblastic  leukemia (ALL): 
treatment 1 
Treatment can span 2 ½ - 3 ½ years and is broken down into 
the following 4 phases: 
1. Induction therapy with the purpose to achieve remission 
by killing most of the cancer cells (chemotherapy drugs 
injected intrathecally, steroids, the anthracyclines)  
2. Consolidation (post-remission) therapy with the goal to 
destroy any remaining leukemia cells in the central 
nervous system (4 - 8 weeks)   
3. Maintenance (low dose) therapy is given to prevent cancer 
cell re-growth (4 weeks) 
4. Preventive therapy to the spinal cord (chemotherapy 
drugs are injected directly into the spinal cord fluid)  
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
treatment 2 
There are 4 main types of the specific treatments : 
• Chemotherapy (all patients need spinal taps to inject 
chemotherapy into the cerebrospinal fluid (CSF) to kill any 
leukemia cells that may have spread to the brain and spinal 
cord)  
• Targeted drug therapy to attack specific abnormalities that 
cause the cancer cell growth 
• Radiation therapy is typically used when the cancer has 
spread to the central nervous system 
• Stem cell transplant (SCT) may be used for patients at risk 
or currently going through a relapse  
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
treatment 3 
Physical Therapy and exercise  are aimed at symptom 
management, preservation of muscle function, pain control, 
and increased quality of life and include: 
• Up to 15 minutes of walking 5x per week   
• Strength training  combined with aerobic exercises 3x per 
week, twice daily, for 30 minutes   
• Pain management (transcutaneous electrical nerve 
stimulation (TENS), hot packs, cold packs, massage, etc.  
• Stretching (sustained stretch, active and passive range of 
motion (ROM), splinting, etc.) 
 
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
treatment 4 
Medications: 
• Chemotherapy drugs: L - asparaginase, Vincristine 
• Steroid: Dexamethasone, Hydrocortisone 
• Drugs for high-risk patients: Daunorubicin, Cytarabine 
• Other drugs: Methotrexate, 6-mercaptopurine  
Novel approaches: 
• For some subtypes of relapsed ALL, aiming at biological 
targets such as the proteasome, in combination with 
chemotherapy, has given promising results in clinical trials 
• Chimeric antigen receptors (CARs) have been developed as 
a promising therapy for ALL 
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia#Diagnosis  
 
 
Acute lymphoblastic  leukemia (ALL): 
prognosis 
• Acute lymphoblastic leukemia is a curable disease, and the 
chance of cure for a specific patient depends on a number 
of prognostic factors (females tend to fare better than 
males; Caucasians are more likely to develop acute 
leukemia than African-Americans, Asians, or Hispanics; 
children 1–10 years of age are most likely to develop ALL 
and to be cured of it; cases in older patients are more likely 
to result from chromosomal abnormalities, etc.)   
• The 5-year survival rate has improved from zero six decades 
ago, to 85% currently, largely because of clinical trials on 
new chemotherapeutic agents and improvements in SCT 
technology 
http://emedicine.medscape.com/article/197802-overview#a6  
 
 
Chronic myelogenous leukemia (CML): 
definition 
Chronic myelogenous (myeloid, myelocytic, 
granulocytic) leukemia (CML) is the clonal 
hematopoietic stem cell disorder with an abnormal 
increase in mature and immature granulocytes (as 
neutrophils, eosinophils, and myelocytes) especially in 
bone marrow and blood, that occurs especially in 
adults, and that is associated with the presence of the 
Philadelphia chromosome CML   
http://www.merriam-webster.com/medical/chronic%20myelogenous%20leukemia  
Chronic myelogenous leukemia (CML): 
epidemiology 
Incidence of CML by age 
http://seer.cancer.gov/statfacts/html/cmyl.html  
Chronic myelogenous leukemia (CML): 
Philadelphia chromosome 
http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44179  
Chronic myelogenous leukemia (CML): 
classification 1 
• Chronic phase: there are few blast cells in the blood and 
bone marrow and there may be no symptoms of leukemia, 
this phase may last from several months to several years  
• Accelerated phase: there are more blast cells in the blood 
and bone marrow, and fewer normal cells  
• Blastic phase (the blast crisis): more than 30% of the cells 
in the blood or bone marrow are blast cells and the blast 
cells may form tumors outside of the bone marrow in 
places such as the bone or lymph nodes 
• Refractory CML: leukemia cells do not decrease even 
though treatment is given  
http://www.medicinenet.com/script/main/art.asp?articlekey=15477  
 
 
Chronic myelogenous leukemia (CML): 
classification 2 
http://www.medicinenet.com/script/main/art.asp?articlekey=15477  
Chronic phase 
Untreated      Treated 
< 15 % blast cells in blood or 
bone marrow 
< 30 % – the sum of blast cells 
and promyelocytes in blood or 
bone marrow 
< 20 % basophile granulocytes 
in peripheral blood 
Thrombocyte count > 100 x 
109/l 
Normal or close to normal 
blood values 
without immature 
granulocytes in the  blood 
Chronic myelogenous leukemia (CML): 
classification 3 
http://www.medicinenet.com/script/main/art.asp?articlekey=15477  
Accelerated phase 
Blast count between 15–29 % in blood or bone marrow 
≥ 30 %, the sum of blast cells and promyelocytes in blood or 
blood marrow 
≥ 20 % basophile granulocytes in blood 
Thrombocyte count < 100 x 109/l, which cannot be explained 
by treatment   
Often also increasing splenomegaly  
new chromosome changes in Ph+ clone 
Chronic myelogenous leukemia (CML): 
classification 4 
http://www.medicinenet.com/script/main/art.asp?articlekey=15477  
Blast phase 
Characterized by >30 % of the cells in blood or bone 
marrow are blasts  
Patients have symptoms of acute leukemia  
Extramedullary illness  
Chronic myelogenous leukemia (CML): 
clinical presentation 1 
• Most patients (~90%) are diagnosed during the 
chronic stage which is most often asymptomatic, 
and may be diagnosed incidentally with an 
elevated white blood cell count on a routine 
laboratory test 
• It can also present with symptoms indicative of 
enlarged spleen and liver and the resulting upper 
quadrant pain this causes  
• The enlarged spleen may put pressure on the 
stomach causing a loss of appetite and resulting 
weight loss 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Classification  
 
 
Chronic myelogenous leukemia (CML): 
clinical presentation 2 
• It may also present with mild fever and night sweats 
due to an elevated basal level of metabolism 
• Some (<10%) are diagnosed during the accelerated 
stage which most often presents bleeding, petechie 
and ecchymosis, when  fevers are most commonly 
the result of opportunistic infections 
• Some patients are initially diagnosed in the blast 
phase in which the symptoms are most likely fever, 
bone pain and an increase in bone marrow fibrosis 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Classification  
 
 
Chronic myelogenous leukemia (CML): 
clinical presentation 3 
Splenomegaly in CML 
http://hubpages.com/health/Clinical-Manifestations-Diagnosis-And-The-Treatment-Plan-Of-Chronic-Myeloid-Leukemia-CML  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis 1 
• CML is often suspected on the basis of a complete blood 
count, which shows increased granulocytes of all types, 
typically including mature myeloid cells 
• Basophils and eosinophils are almost universally increased; 
this feature may help differentiate CML from a leukemoid 
reaction 
• A bone marrow biopsy is often performed as part of the 
evaluation for CML, and CML is diagnosed by cytogenetics 
that detects the translocation t(9;22)(q34;q11.2) which 
involves the ABL1 gene in chromosome 9 and the BCR gene 
in chromosome 22  
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Classification  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis 2 
• Thus, CML can be detected by routine cytogenetics, and 
the involved genes BCR-ABL1 can be detected 
by fluorescent in situ hybridization, as well as by polymeric 
chain reaction (PCR)  
• Controversy exists over so-called Ph-negative CML, or cases 
of suspected CML in which the Philadelphia chromosome 
cannot be detected: many such patients in fact have 
complex chromosomal abnormalities that mask the (9;22) 
translocation, or have evidence of the translocation in spite 
of normal routine karyotyping  
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Classification  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis 3 
• The small subset of patients without detectable molecular 
evidence of bcr-abl fusion may be better classified as 
having an undifferentiated 
myelodysplastic/myeloproliferative disorder, as their clinical 
course tends to be different from patients with CML  
• CML must be distinguished from a leukemoid reaction, 
which can have a similar appearance on a blood smear 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Classification  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis 3 
A small, hypolobated megakaryocyte (center of field) in a 
bone marrow aspirate, typically of CML 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis  
Immunophenotyping 
http://www.medscape.com/viewarticle/495047_3  
 
 
Chronic myelogenous leukemia (CML): 
treatment 1 
• The only curative treatment for CML is a bone marrow 
transplant or an allogeneic stem cell transplant 
• Other than this there are four major mainstays of 
treatment in CML: 
• treatment with tyrosine kinase inhibitors 
• myelosuppressive or leukopheresis therapy (to 
counteract the leucocytosis during early treatment) 
• splenectomy and interferon alfa-2b treatment  
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 2 
Chronic phase 
• In the past, antimetabolites 
(e.g., cytarabine, hydroxyurea), alkylating agents, interferon 
alfa 2b, and steroids were used as treatments of CML in the 
chronic phase, but since the 2000s have been replaced 
by Bcr-Abl tyrosine-kinase inhibitor drugs that specifically 
target BCR-ABL, the constitutively activated tyrosine kinase 
fusion protein caused by the Philadelphia 
chromosome translocation  
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 3 
Chronic phase 
• Despite the move to replacing cytotoxic antineoplastics 
(standard anticancer drugs) with tyrosine kinase inhibitors 
sometimes hydroxyurea is still used to counteract the high 
WBCs encountered during treatment with tyrosine kinase 
inhibitors like imatinib; in these situations it may be the 
preferred myelosuppressive agent due to its relative lack of 
leukemogenic effects and hence the relative lack of 
potential for secondary haematologic malignancies to 
result from treatment 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 4 
Imatinib 
• The first of this new class of drugs was imatinib mesylate, 
approved by the U.S. Food and Drug Administration (FDA) 
in 2001 
• Imatinib was found to inhibit the progression of CML in the 
majority of patients (65–75%) sufficiently to achieve 
regrowth of their normal bone marrow stem cell 
population (a cytogenetic response) with stable 
proportions of maturing white blood cells 
• Since the advent of imatinib, CML has become the first 
cancer in which a standard medical treatment may give to 
the patient a normal life expectancy 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 5 
Dasatinib, nilotinib and radotinib 
• Dasatinib, blocks several further oncogenic proteins, in 
addition to more potent inhibition of the BCR-ABL protein, 
and was initially approved in 2007 by the US FDA to treat 
CML in patients who were either resistant to or intolerant 
of imatinib 
• Nilotinib, was also approved by the FDA for the same 
indication in 2010 
• Radotinib joined the class of novel agents in the inhibition 
of the BCR-ABL protein and was approved in South Korea in 
2012 for patients resistant to or intolerant of imatinib 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 5 
Treatment-resistant CML 
• Two approaches were developed to the treatment of CML 
as a result: 
• In September 2012, the FDA approved a non BCR-ABL 
targeted agent omacetaxine, administered 
subcutaneously (under the skin) in patients who had 
failed with imatinib and exhibited T315I kinase domain 
mutation 
• In December 2012 , the FDA approved a new pan-BCR-
ABL inhibitor Ponatinib which showed (for the first time) 
efficacy against T315I, as well as all other known 
mutations of the oncoprotein    
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 6 
Vaccination 
 
In 2005, encouraging but mixed results of vaccination were 
reported with the BCR/abl p210 fusion protein in patients 
with stable disease, with GM-CSF as an adjuvant  
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
prognosis 
• Before the advent of tyrosine kinase inhibitors, the median 
survival time for CML patients had been about 3–5 years 
from time of diagnosis 
• With the use of tyrosine kinase inhibitors, survival rates 
have improved dramatically 
• A 2006 follow up of 553 patients using imatinib found an 
overall survival rate of 89% after five years  
• A 2011 follow up of 832 patients using imatinib who 
achieved a stable cytogenetic response found an overall 
survival rate of 95.2% after 8 years, which is similar to the 
rate in the general population. Less than 1% of patients 
died because of leukemia progression 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Prognosis  
 
 
Chronic lymphocytic leukemia (CLL): 
definition 
Chronic lymphocytic  leukemia (CLL) is a monoclonal 
disorder characterized by a progressive accumulation 
of small, mature-appearing functionally incompetent 
lymphocytes in blood, bone marrow, and organs 
http://oncolex.org/Leukemia/Background/Staging  
Chronic lymphocytic leukemia (CLL): 
epidemiology 
Incidence of CLL by age 
https://www.onkopedia-guidelines.info/en/onkopedia/archive/guidelines/chronic-lymphocytic-leukemia/version-30052015T091206/@@view/html/index.html  
Chronic lymphocytic leukemia (CLL): 
classification 1 
http://oncolex.org/Leukemia/Background/Staging  
 
 
Stage division of CLL according to Binet 
Criteria Stage 
  A B C 
Number of involved lymph 
node regions 
0–2 3–5 0–5 
Hemoglobin (g/dl) >10 >10 <10 
Thrombocytes (109/l) >100 >100 <100 
Survival (years) >10 5 2.6 
Chronic lymphocytic leukemia (CLL): 
classification 2 
Stage division of CLL according to Rai  
0   - characterized by absolute lymphocytosis (>15,000/mm3) without 
adenopathy, hepatosplenomegaly, anemia, or thrombocytopenia 
I  - characterized by absolute lymphocytosis with lymphadenopathy 
without hepatosplenomegaly, anemia, or thrombocytopenia 
II  - characterized by absolute lymphocytosis with either hepatomegaly 
or splenomegaly with or without lymphadenopathy 
III - characterized by absolute lymphocytosis and anemia (hemoglobin 
<11 g/dL) with or without lymphadenopathy, hepatomegaly, or 
splenomegaly 
IV - characterized by absolute lymphocytosis and thrombocytopenia 
(<100,000/mm3) with or without lymphadenopathy, hepatomegaly, 
splenomegaly, or anemia 
https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia#Diagnosis  
 
 
Chronic lymphocytic leukemia (CLL): 
clinical presentation 1 
• About 40%-60% of patients with CLL are diagnosed in the 
absence of disease-related symptoms, even with very high 
numbers of circulating lymphocytes >100 × 109/l 
• Frequently, the presence of lymphadenopathy or an 
abnormal CBC performed during a routine medical 
examination is the only reason to consider the diagnosis  
• The remaining patients may present with weakness, 
fatigue, night sweats, fever, and may be with or without 
infections or autoimmune diseases 
• Physical examination generally reveals nontender, painless, 
and mobile lymphadenopathy, splenomegaly, or 
hepatomegaly 
http://theoncologist.alphamedpress.org/content/4/5/352.full  
 
 
Chronic lymphocytic leukemia (CLL): 
clinical presentation 2 
• Metabolic abnormalities (e.g., hyperuricemia) or 
mechanical disorders (e.g., airway obstruction) related to 
the tumor burden, may also be present 
• Any part of the body, including skin and meninges may be 
infiltrated by CLL cells  
• Manifestations of bone marrow (BM) involvement, 
particularly significant anemia (hemoglobin <11g/dl) or 
thrombocytopenia (platelets count <100 × 109/l), are noted 
at presentation in 15% of CLL patients 
• A positive direct antiglobulin test (DAT) is present in about 
20% of patients at diagnosis but is not commonly 
associated with hemolytic anemia   
http://theoncologist.alphamedpress.org/content/4/5/352.full  
 
 
Chronic lymphocytic leukemia (CLL): 
clinical presentation 3 
Massive adenopathy involving the neck, 
from the level of the mastoid to the 
supraclavicular fossa, and large nodal 
masses in both axillae 
http://escholarship.org/uc/item/8ts5q1b3  http://www.nejm.org/doi/full/10.1056/NEJMicm071065  
 
 
Zosteriform B-Cell 
CLL infiltration 
Chronic lymphocytic leukemia (CLL): 
diagnosis 1 
The National Cancer Institute-Sponsored Working Group 
diagnosis and response criteria for CLL 
• The peripheral blood should exhibit an increase in the 
number of small mature-appearing lymphocytes to 
>5,000/μl 
• The bone marrow (BM) aspirate smear must show >30% of 
all nucleated cells to be lymphoid 
• Subsequently, a BM examination is indicated primarily to 
evaluate response to treatment or to assess normal 
elements if there is an unexplained anemia or 
thrombocytopenia 
http://theoncologist.alphamedpress.org/content/4/5/352.full  
 
 
Chronic lymphocytic leukemia (CLL): 
diagnosis 2 
B-cell chronic lymphocytic 
leukemia: compare the cell size of 
CLL cells with a single large 
granular lymphocyte (curved 
arrow)  
http://www.pathpedia.com/education/eatlas/histopathology/blood_cells/chronic_lymphocytic_leukemia_(cll)_b-cell.aspx  http://www.forpath.org/workshops/minutes/0011/case03.asp  
 
 
The BM biopsy shows a global 
cellularity within normal range, 
although somewhat 
heterogeneous: three cell lines 
present with maturation 
Chronic lymphocytic leukemia (CLL): 
diagnosis  
Immunophenotyping 
http://www.medscape.com/viewarticle/490055_3  
 
 
Chronic lymphocytic leukemia (CLL): 
treatment 1 
• CLL treatment focuses on controlling the disease and its 
symptoms rather than on an outright cure 
• CLL is treated by chemotherapy, radiation therapy, 
biological therapy, or bone marrow transplantation 
• Symptoms are sometimes treated surgically (splenectomy 
removal of enlarged spleen) or by radiation therapy ("de-
bulking" swollen lymph nodes) 
• An initial treatment regimen that 
contains fludarabine, cyclophosphamide, 
and rituximab (known as FCR) has demonstrated higher 
overall response rates and complete response rates 
https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia#Diagnosis  
 
 
Chronic lymphocytic leukemia (CLL): 
treatment 2 
• Physicians use a “watchful waiting” mode  until the disease 
progressed, but the novel prognostic markers indicate that 
50% of patients have a poor outcome 
• Since CLL cells must interact with the stroma in bone 
marrow or lymphoid tissues to survive, these interactions 
need to be explored as targets of innovative therapies, and 
specific inhibition of the B-cell receptor signaling pathway, 
as  targeting the actively proliferating cells that maintain 
the CLL clone by a cell-cycle–active agent may be an option 
• Since as 20% of patients with the worst prognostic markers 
have stereotypic antigen receptors, they may be valuable 
points of attack  
http://www.nejm.org/doi/full/10.1056/NEJMra041720  
Chronic lymphocytic leukemia (CLL): 
prognosis 
• Prognosis depends on the subtype 
• Some subtypes have a median survival of 6–8 years, 
while others have a median survival of 22 years 
(which is a normal lifespan for older patients) 
• Telomere length has been suggested to be a 
valuable prognostic indicator of survival 
https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia#Diagnosis  
 
 
Prophylaxis 
Patients with leukemia in periods of severe 
granulocytopenia and thrombocytopenia related to 
the specific antileukemic therapies administered 
demand secondary prophylaxis with antifungals and 
antibiotics  
http://www.uptodate.com/contents/prevention-of-infections-in-patients-with-chronic-lymphocytic-leukemia  
Abbreviations  
• ALL - acute lymphoblastic leukemia  
• AML - acute myelogenous leukemia  
• BM – bone marrow  
• CALLA - common acute lymphoblastic leukemia antigen  
• CARs - Chimeric antigen receptors  
• CLL - chronic lymphocytic leukemia  
• CML - chronic myelogenous leukemia  
• CNS - central nervous system 
• DCL - donor cell leukemia 
• FAB - French-American-British classification 
• FFP - fresh frozen plasma 
• ROM - range of motion 
• SCT - stem cell transplant 
• TdT - terminal deoxynucleotidyl transferase  
• TENS - transcutaneous electrical nerve stimulation 
• WHO - World Health Organization  
• PCR  - polymeric chain reaction 
• FDA - U.S. Food and Drug Administration  
Diagnostic guidelines 
• Peripheral T-Cell Lymphomas: ESMO Clinical Practice Guidelines  
• Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines 
• Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines 
• Hairy Cell Leukaemia: ESMO Clinical Practice Guidelines 
• Philadelphia Chromosome-Negative Chronic Myeloproliferative 
Neoplasms: ESMO Clinical Practice Guidelines 
• Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines 
• New aspects of the updated guidelines for the diagnosis and 
treatment of chronic lymphocytic leukemia  
• Leukemia: An Overview for Primary Care 
 
